Theravance Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Theravance Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q2 2024.
  • Theravance Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$16.5M, a 5.65% decline year-over-year.
  • Theravance Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$45.7M, a 105% decline year-over-year.
  • Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$55.2M, a 106% decline from 2022.
  • Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $872M.
  • Theravance Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$199M, a 28.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$45.7M -$16.5M -$884K -5.65% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$44.8M -$11.7M +$10.4M +47.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$55.2M -$8.51M +$1.85M +17.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$57M -$8.95M -$926M -101% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-01
Q2 2023 $869M -$15.6M -$7.45M -91% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $876M -$22.1M +$3.86M +14.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $872M -$10.4M +$21.7M +67.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 $850M $917M +$952M Jul 1, 2022 Sep 30, 2022 10-K 2024-03-01
Q2 2022 -$101M -$8.19M +$44.2M +84.4% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-01
Q1 2022 -$146M -$25.9M +$53.7M +67.4% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-01
Q4 2021 -$199M -$32M +$26.4M +45.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$226M -$35.3M +$38.3M +52.1% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-01
Q2 2021 -$264M -$52.4M +$10.5M +16.7% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-01
Q1 2021 -$275M -$79.7M +$3.37M +4.06% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-01
Q4 2020 -$278M -$58.4M +$7.17M +10.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$285M -$73.6M -$15.2M -26% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$270M -$62.9M -$23M -57.9% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$247M -$83.1M -$10.5M -14.4% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 -$236M -$65.6M -$15.4M -30.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$221M -$58.4M +$1M +1.69% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 -$222M -$39.8M +$980K +2.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 -$223M -$72.6M -$7.49M -11.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 -$216M -$50.2M +$36.7M +42.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$252M -$59.4M +$7.44M +11.1% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$260M -$40.8M +$25.5M +38.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$285M -$65.1M +$232K +0.36% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$285M -$86.9M -$19.6M -29.1% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$266M -$66.9M -$32.9M -96.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$233M -$66.3M -$19.1M -40.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$214M -$65.3M -$23.2M -55% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$191M -$67.3M -$22.5M -50.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-28
Q3 2016 -$168M -$34M +$13.4M +28.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-28
Q2 2016 -$182M -$47.2M +$378K +0.79% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-28
Q1 2016 -$182M -$42.2M +$324K +0.76% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-28
Q4 2015 -$182M -$44.8M +$19.5M +30.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$202M -$47.3M +$7.18M +13.2% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$209M -$47.6M +$10.6M +18.2% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$219M -$42.5M +$17.5M +29.2% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$237M -$64.3M -$20.2M -45.9% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$217M -$54.5M -$13.4M -32.7% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-11
Q2 2014 -$203M -$58.2M -$19.3M -49.5% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-11
Q1 2014 -$184M -$60M -$27.8M -86.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-11
Q4 2013 -$156M -$44.1M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-13
Q3 2013 -$41.1M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-13
Q2 2013 -$39M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-13
Q1 2013 -$32.2M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.